0.03
-0.00045(-1.31%)
Currency In USD
| Previous Close | 0.03 |
| Open | 0.04 |
| Day High | 0.04 |
| Day Low | 0.03 |
| 52-Week High | 30.8 |
| 52-Week Low | 0.03 |
| Volume | 382,097 |
| Average Volume | 496,931 |
| Market Cap | 40,982 |
| PE | -0.01 |
| EPS | -2.3 |
| Moving Average 50 Days | 0.05 |
| Moving Average 200 Days | 4.09 |
| Change | -0 |
If you invested $1000 in CERo Therapeutics Holdings, Inc. (CERO) since IPO date, it would be worth $0 as of March 09, 2026 at a share price of $0.034. Whereas If you bought $1000 worth of CERo Therapeutics Holdings, Inc. (CERO) shares 3 years ago, it would be worth $0 as of March 09, 2026 at a share price of $0.034.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
GlobeNewswire Inc.
Feb 04, 2026 2:05 PM GMT
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 04
CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML
GlobeNewswire Inc.
Jan 07, 2026 2:09 PM GMT
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), a